PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22694757-0	2012	ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion.	fasudil	15-22	C-C motif chemokine ligand 2	Homo sapiens	55-60	
22694757-10	2012	Fasudil also decreased MCP-1 concentration in HUVEC supernatants, but increased sVCAM-1 shedding into the media.	fasudil	0-7	C-C motif chemokine ligand 2	Homo sapiens	23-28	
22694757-11	2012	In human diabetic subjects, 2 weeks of fasudil treatment significantly decreased serum MCP-1 level from 27.9 +- 10.6 pg/ml to 13.8 +- 7.0 pg/ml (P < 0.05), while sVCAM-1 increased from 23.2 +- 7.5 ng/ml to 39.7 +- 5.6 ng/ml after fasudil treatment (P < 0.05).	fasudil	39-46	C-C motif chemokine ligand 2	Homo sapiens	87-92	
22694757-12	2012	CONCLUSIONS: Treatment with the Rho/ROCK pathway inhibitor fasudil attenuated HG-induced monocyte-endothelial cell adhesion, possibly by reducing endothelial expression of VCAM-1 and MCP-1.	fasudil	59-66	C-C motif chemokine ligand 2	Homo sapiens	183-188